Related Experiment Video
Updated: Jan 25, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
K Hastings1, H A Yu2, W Wei3
1Yale Cancer Center, New Haven.
Background:
Although EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; however, there is a lack of understanding of the characteristics of EGFR mutant lung tumors responsive to immune checkpoint blockade.
Patients And Methods:
We retrospectively analyzed de-identified clinical and molecular data on 171 cases of EGFR mutant lung tumors treated with immune checkpoint inhibitors from the Yale Cancer Center, Memorial Sloan Kettering Cancer Center, University of California Los Angeles, and Dana Farber Cancer Institute. A separate cohort of 383 EGFR mutant lung cancer cases with sequencing data available from the Yale Cancer Center, Memorial Sloan Kettering Cancer Center, and The Cancer Genome Atlas was compiled to assess the relationship between tumor mutation burden and specific EGFR alterations.
Results:
Compared with 212 EGFR wild-type lung cancers, outcomes with programmed cell death 1 or programmed death-ligand 1 (PD-(L)1) blockade were worse in patients with lung tumors harboring alterations in exon 19 of EGFR (EGFRΔ19) but similar for EGFRL858R lung tumors. EGFRT790M status and PD-L1 expression did not impact response or survival outcomes to immune checkpoint blockade. PD-L1 expression was similar across EGFR alleles. Lung tumors with EGFRΔ19 alterations harbored a lower tumor mutation burden compared with EGFRL858R lung tumors despite similar smoking history.
Conclusions:
EGFR mutant tumors have generally low response to immune checkpoint inhibitors, but outcomes vary by allele. Understanding the heterogeneity of EGFR mutant tumors may be informative for establishing the benefits and uses of PD-(L)1 therapies for patients with this disease.
Insights
Outcomes for EGFR mutant lung cancer treated with immune checkpoint inhibitors (ICIs) vary by specific EGFR alteration. While EGFR exon 19 deletions (EGFRΔ19) show poorer response, EGFRL858R mutations have similar outcomes to EGFR wild-type tumors.
Area of Science:
- Oncology
- Genetics
- Immunotherapy
Background:
- Epidermal Growth Factor Receptor (EGFR) mutant lung tumors generally show limited response to immune checkpoint blockade (ICB).
- However, a subset of these tumors does respond, indicating a need to understand the characteristics of responsive EGFR mutant lung tumors.
- This study investigates the heterogeneity within EGFR mutant lung cancers concerning their response to ICB.
Purpose of the Study:
- To analyze the clinical and molecular characteristics of EGFR mutant lung tumors treated with immune checkpoint inhibitors (ICIs).
- To assess the relationship between tumor mutation burden and specific EGFR alterations in lung cancer.
- To determine how different EGFR mutations (e.g., EGFRΔ19, EGFRL858R) and T790M status affect outcomes with PD-(L)1 blockade.
Main Methods:
- Retrospective analysis of 171 EGFR mutant lung tumors treated with ICIs from multiple cancer centers.
- Compilation of a separate cohort of 383 EGFR mutant lung cancer cases with sequencing data.
- Assessment of programmed cell death 1 (PD-1) or programmed death-ligand 1 (PD-L1) blockade outcomes, tumor mutation burden, and EGFR alterations.
Main Results:
- Patients with EGFR exon 19 deletions (EGFRΔ19) had worse outcomes with PD-(L)1 blockade compared to EGFR wild-type lung cancers.
- Outcomes for EGFRL858R mutant lung tumors were similar to EGFR wild-type.
- EGFR T790M status and PD-L1 expression did not significantly impact response or survival with ICB, and PD-L1 expression was consistent across EGFR alleles. EGFRΔ19 tumors had lower tumor mutation burden than EGFRL858R tumors.
Conclusions:
- Response to immune checkpoint inhibitors in EGFR mutant lung cancer is allele-dependent.
- Understanding the heterogeneity of EGFR mutations is crucial for optimizing PD-(L)1 therapy selection and application in lung cancer patients.
- Further research into the specific characteristics of responsive EGFR mutant tumors is warranted.
More Related Videos
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
11:31Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
Published on: May 20, 2016
Related Concept Videos
01:36Humoral Immune Responses
01:40Cell-mediated Immune Responses
01:23Cells of the Adaptive Immune Response
01:28Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
02:21Cancers Originate from Somatic Mutations in a Single Cell
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...